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Abstract
Objective: Transforming growth factor beta (TGFβ)-activated kinase 1 (TAK1) is a MAP kinase
kinase kinase involved in numerous signalling pathways and is strongly implicated in cardiac
hypertrophy and heart failure. TGFβ is also associated with hypertension and heart disease, and
evidence suggests that TGFβ1 and TAK1 act together in a cardiac stress signalling pathway.
Canonical TGFβ signalling is mediated through Smad transcription factors, but TGFβ can also rapidly
activate TAK1. The activation of the Smad cascade is well characterised, but little is known about
how TAK1 is activated in response to TGFβ, and no direct link between any MAPK kinase pathway
and the TGFβ receptors has yet been established. Since TAK1 is activated by TGFβ within 1 min in
cardiomyocytes, we hypothesised there might be a direct interaction between TAK1 and one of the
TGFβ receptors.
Methods: We used a combination of in vitro binding assays and co-immunoprecipitation (IP)
experiments to investigate whether TAK1 interacted with the type I (ALK1 or ALK5) or type II
(TBRII) TGFβ receptors. Interactions between endogenous proteins were tested using mouse
myoblast and rat cardiomyocyte cells.
Results: Immunoprecipitation and in vitro binding assays show that TAK1 binds directly to TBRII.
Precipitation of endogenous TAK1 protein in rat cardiomyocytes shows that, in addition to a direct
association with TBRII, it also interacts indirectly with ALK5.
Conclusions: We describe a novel and specific interaction between TAK1 and TBRII which, for
the first time, directly links TAK1 to the TGFβ signalling cascade and potentially explains how
TGFβ signalling in cardiomyocytes mediates a hypertrophic response.
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1. Introduction
The molecular pathways that couple increased haemodynamic load to myocardial hypertrophy,
cardiomyocyte apoptosis and subsequent heart failure are complex and represent an important
challenge in current cardiovascular medicine [1-4]. Recently, an important cytokine,
transforming growth factor β1 (TGFβ1), has been shown to be pivotal in mediating the cardiac
hypertrophic response induced by angiotensin II [5-8]. TGFβ1 expression is stimulated by
Angiotensin II and it becomes highly expressed in hypertrophic myocardium, where it regulates
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a wide range of cellular functions including proliferation, differentiation, apoptosis and fibrosis
[9,10].
To promote signalling, TGFβ first binds to the TGFβ type II receptor (TBRII) at the cell surface
stimulating it to activate the TGFβ type I receptor (TBRI), which in turn phosphorylates
downstream Smad proteins. These activated Smad complexes translocate to the nucleus where
they regulate the transcription of TGFβ target genes [11,12].In addition to the canonical
TGFβ signalling pathway, TGFβ has been shown to rapidly activate TGFβ activated kinase 1
(TAK1), a MAP kinase kinase kinase [13]. In cardiomyocytes, TAK1 is activated within a
minute of exposure to TGFβ1 [13,14] and there is clear evidence that TAK1 is also an important
regulator of the hypertrophic response. Firstly, TAK1 is activated in cardiomyocytes following
pressure overload generated by aortic constriction; secondly, cardiac specific over-expression
of activated TAK1 in a transgenic mouse leads to cardiac hypertrophy and heart failure; and
thirdly, dominant negative TAK1 protein can inhibit TGFβ-induced hypertrophic events in
mouse cardiomyocytes and fibroblasts [14,15]. This particularly illustrates the importance of
TAK1 as a mediator of cardiac TGFβ signalling, although TAK1 also interacts with the BMP
and IL-1 signalling pathways and is arguably a central protein in the cellular signalling network
[16-18]. Active TAK1 phosphorylates MKK3 and/or MKK6, which in turn phosphorylate p38.
Increased p38 activity is strongly associated with typical hypertrophic responses including
inflammation, fibroblast proliferation, hypertrophy and apoptosis [19-22].
The mechanism of intracellular TAK1 activation by extracellular TGFβ stimulation is not well
understood. Early work showed that TAK1 is activated by TAK1-binding protein (TAB1),
which is required for normal cardiac development [23,24], but this does not explain the rapid
activation response to extracellular TGFβ. Here we describe a specific interaction between
TAK1 and the type II TGFβ receptor (TBRII), which directly links TAK1 to the primary step
of the TGFβ signalling cascade. This work is important not only as the first demonstration of
a direct connection between a TGFβ receptor and TAK1 but also because of its potential
importance in the early signalling events leading to cardiac hypertrophy and heart failure.
2. Methods
2.1. Plasmids and antibodies
HA-TAK1 and FLAG-TAK1 were cloned into pcDNA3.1+ (Invitrogen). The following
plasmids were kind gifts: pCMV.HA-ALK1, pCMV.HA-ALK5, and pcDNA.HA-TBRII (P.
ten Dijke), pCMV.myc-TAB1 (T. Ishitani), pGEX4T.mTBRII (P. Eyers), pXpressTAK1A,
pXpressTAK1B and pXpressTAK1D (F. Guesdon), pcDL.HA-MLTKβ (E. Nishida). TAK1
was cloned into vector pFTX9 [25] to generate pFTX9.mTAK1 for in vitro transcription/
translation. pGEX2T.mEndoglin GST-fusion plasmid was generated by PCR cloning of
Endoglin cytoplasmic region cDNA into pGEX2T (Pharmacia). Primary antibodies were anti-
TAK1 (sc-7967), anti-TBRII (sc-220) and anti-ALK5 (sc-398) antibodies (Santa Cruz), anti-
Myc antibody (Oncogene Research Products), 3F10 anti-HA antibody (Roche), M2 anti-Flag
antibody (Sigma) and anti-Xpress antibody (Invitrogen). Secondary antibodies were
conjugated to HRP (DAKO) or FITC/Texas Red (Vector Laboratories).
2.2. Cell culture and transient transfections
Cos7 (African green monkey kidney) and 293T (Human embryonal kidney) cells were used
for transfection studies and were cultured in Dulbecco's Modified Eagles Medium (DMEM)
supplemented with 10% Foetal Calf Serum (FCS) and 4 mM glutamine. Cells were transfected
with 1 μg of plasmid using FuGene6 (Roche) and incubated for 24 to 48 h before appropriate
treatment.
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To examine endogenous protein interactions, C2C12 (mouse muscle myoblast) cells were
cultured in DMEM supplemented with 15% FCS and 4 mM glutamine, whilst H9C2 (rat
cardiomyocyte) cells were cultured in high glucose (4500 mg/ml) DMEM supplemented with
10% FCS and 4 mM glutamine.
2.3. Immunofluorescence microscopy
Cos7 cells were co-transfected with pcDNA3.1 + FLAG-TAK1 and pcDNA.HA-TBRII
plasmids and fixed in 100% methanol after 24 h. Cells were permeabilised in PBS/0.5% Triton
X-100 for 30 min at 4 °C, blocked in PBS/0.1% Tween-20/10% FCS for 30 min at 37 °C and
treated with anti-TAK1 antibody for 1 h at 37 °C before washing in PBS/0.1% Tween-20 and
incubation with FITC-conjugated secondary antibody for 1 h (37 °C). For double staining, cells
were washed thoroughly again and incubated with goat polyclonal anti-TBRII primary
antibody, followed by Texas Red-conjugated secondary antibody, as before. Slides were
mounted in Vectashield with DAPI (Vector laboratories). Images were acquired using a Zeiss
Axioplan II microscope and Axiovision software.
2.4. Preparation of cell extracts and GST fusion proteins
To prepare protein extracts for immunoprecipitation, cells were harvested in ice-cold NTT lysis
buffer (100 mM NaCl, 50 mM Tris–HCl pH 8, 1% Triton X-100, 10 mM NaF, +protease
inhibitor cocktail [bestatin, leupeptin, pepstatin A, aprotinin, E64; Sigma]) and homogenized
through a 25 Gauge syringe needle. Cell debris was removed by microcentrifugation and
supernatant was used for immunoprecipitation experiments. GST, GST–Endoglin and GST–
TBRII fusion proteins were purified from BL21 Escherichia coli extracts using Glutathione
Sepharose 4B resin followed by elution with 10 mM reduced glutathione, 50 mM Tris pH 8.
2.5. Immunoblotting and immunoprecipitation
For immunoblot analysis, protein was transferred to nitrocellulose membrane, blocked with
PBS/0.3% Tween-20/3% skimmed milk before incubation with primary antibody. Washed
membranes were incubated with HRP-conjugated secondary antibody and proteins visualised
using ECL. For immunoprecipitation, cell lysates were incubated for 2 to 12 h at 4 °C with the
indicated antibody. IgG was precipitated by incubation with sepharose-conjugated protein A
(Sigma) for 1 to 2 h at 4 °C followed by microcentrifugation. The immunoprecipitate was
washed in high salt NTT buffer (400 mM NaCl, 50 mM Tris–HCl pH 8.0, 1% Triton X-100,
10 mM NaF, +protease inhibitor cocktail) and analyzed by SDS polyacrylamide gel
electrophoresis (PAGE) and immunoblotting.
2.6. In vitro binding assay
[35S]-methionine labelled TAK1 protein was prepared using a TnT T7 Quick coupled
transcription/translation system (Promega) mixed with purified GST and GST fusion proteins,
and then precipitated with Glutathione Sepharose 4B resin. GST pull down proteins were
washed three times in NTT buffer, separated by SDS-PAGE and radioactivity was detected
with a BAS 2000 image analyzer (Fuji).
3. Results
3.1. TAK1 protein interacts specifically with the type II TGFβ receptor (TBRII)
The role of TAK1 in cardiac hypertrophy and its extremely rapid activation by TGFβ1 [14]
led us to hypothesise that there may be a direct interaction between TAK1 and a ligand-binding
TGFβ receptor. In order to test this hypothesis we performed immunoprecipitation (IP)
experiments on 293T cells that co-expressed TAK1 with one of the type I TGFβ receptors
(ALK5 or ALK1) or the type II TGFβ receptor (TBRII). Ectopically expressed FLAG-tagged
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TAK1 protein was immunoprecipitated using monoclonal anti-FLAG antibody. The type I
receptors (ALK5 and ALK1) and type II receptor (TBRII) all carried Haemaglutinin (HA)
epitope tags at their N-terminus and were all detected in the cell lysates (Fig. 1, 2nd panel).
However, immunoblot analysis of the TAK1 immunoprecipitate detected only the TBRII
protein and not the ALK5 or ALK1 type I receptor proteins (Fig. 1, 3rd panel). Conversely,
when all three TGFβ receptors were immunoprecipitated with anti-HA antibody, TAK1 protein
could only be detected in the TBRII immunoprecipitate and not in the ALK5 or ALK1
immunoprecipitate (Fig. 1, bottom panel). These results demonstrate that TAK1 interacts with
TBRII but not with type I TGFβ receptors. Immunofluorescence microscopy of Cos7 cells co-
transfected with both TAK1 and TBRII plasmids showed that cells clearly expressed both
TAK1 and TBRII proteins and that there was a significant amount of co-localisation both in
the cytoplasm and at areas of the cell membrane (Fig. 2A).
3.2. TAK1 protein can interact directly with TBRII
In order to determine that the TAK1 interaction with TBRII was not due to the presence of any
specific intermediate binding proteins, an in vitro binding assay was performed. 35S-labelled
TAK1 protein was generated by in vitro transcription and translation and then mixed directly
with GST fusion proteins of the cytoplasmic domains of TBRII and the type III TGFβ receptor,
Endoglin. GST fusion proteins were precipitated with Glutathione Sepharose resin and
precipitates were analyzed for the presence of 35S-TAK1. Radiolabelled TAK1 protein was
clearly detectable after precipitation of GST–TBRII protein but not in precipitates of GST–
Endoglin or GST alone (Fig. 2B). The in vitro binding assay strongly suggests that TAK1 is
capable of directly interacting with the cytoplasmic domain of TBRII and that the co-
immunoprecipitation results were not due to the action of an intermediary binding or scaffold
protein.
3.3. Three isoforms of TAK1 can interact with TBRII
There are four isoforms of human TAK1 (TAK1A, B, C and D) and all are very similar to each
other but vary significantly at their C-Terminal ends [26]. TAK1A is the most abundant across
all tissue types and the one we have used in all other experiments. TAK1A, B and C are
ubiquitously expressed whereas TAK1D has a more restricted pattern of expression. All four
isoforms are expressed in cardiac tissue with TAK1A and B expressed at the highest levels
[26]. In order to further characterise the TAK1/TBRII interaction we selected three TAK1
isoforms—A and B (due to their abundance in heart) and D (which differed most at the C
terminus—Fig. 3B) and co-expressed them with TBRII in Cos7 cells. All three isoforms carried
N-terminal Xpress epitope tags (Promega) and were immunoprecipitated from whole cell
extracts with an anti-Xpress antibody (Fig. 3A). Immunoblot analysis with anti-TBRII antibody
detected TBRII protein equally in all three immunoprecipitates (Fig. 3A—bottom panel).
TBRII therefore interacted with all three TAK1 isoforms tested.
3.4. TBRII interacts specifically with TAK1
To confirm that the TAK1/TBRII interaction is specific to TAK1, TBRII protein was co-
expressed in Cos7 cells with either TAK1 or MLK-like triple kinase β (MLTKβ—[27]), a
closely related MAPKKK with 45% homology to TAK1. Both TAK1 and MLTKβ proteins
were immunoprecipitated from whole cell lysates. Immunoblot analysis with anti-TBRII
antibody detected TBRII protein in the TAK1 precipitate but not in the MLTKβ precipitate
(Fig. 4). The results confirm that TBRII specifically interacts with TAK1 and not with a related
kinase.
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3.5. TAK1 and TBRII proteins interact endogenously
Endogenous interactions between TAK1 and TBRII were investigated in both mouse myoblast
(C2C12) and rat cardiomyocyte (H9C2) cell lines. C2C12 cell lysates were
immunoprecipitated with anti-TAK1 monoclonal antibody in order to pull down endogenous
TAK1 protein. Immunoblot analysis with anti-TBRII antibody clearly detected endogenous
TBRII protein in the TAK1 precipitate (Fig. 5A, i). A reciprocal immunoprecipitation with
anti-TBRII antibody on C2C12 cell lysate also precipitated endogenous TAK1 protein as
detected by immunoblot analysis (Fig. 5A, ii). These experiments confirmed an interaction
between TAK1 and TBRII proteins at endogenous levels. Similar experiments were also
performed on H9C2 cardiomyocyte cells. Immunoblot analysis with anti-TBRII antibody again
clearly detected endogenous TBRII protein in the TAK1 precipitate (Fig. 5B, i). The results
confirmed that TAK1 and TBRII proteins interact at endogenous protein levels in
cardiomyocyte cells. We also tested whether endogenous TAK1 protein interacted with ALK5
indirectly, perhaps through the known association of ALK5 with TBRII. This was tested in the
cardiomyocyte cells by immunoblot analysis of the endogenous TAK1 precipitate with anti-
ALK5 antibody and clearly shows that endogenous ALK5 is indeed present in association with
TAK1 (Fig. 5B, ii). As TAK1 did not interact directly with ALK5 when both were over-
expressed (Fig. 1) it is likely to be an indirect interaction, as indicated in Fig. 6.
4. Discussion
Angiotensin II has been well characterised as a promoter of cardiac hypertrophy [28-30] and
more recently it has been shown to trigger the hypertrophic response through TGFβ1 signalling
[5,6]. Of the downstream proteins known to be activated by TGFβ signalling, in vivo data
suggests that TAK1 is critically important in the cardiac hypertrophic response [14] and TAK1
inhibitors can reduce fibrosis and inflammation [15,16]. However, the mechanism by which
(intracellular) TAK1 is rapidly activated in cardiomyocytes by (extracellular) TGFβ ligand
remains unresolved. Here we report an important step forward, as we have discovered a novel
interaction between TAK1 and the cytoplasmic domain of TBRII that potentially explains the
swift response of TAK1 to TGFβ. We used reciprocal co-immunoprecipitations (co-IPs) and
in vitro GST pull down assays to show that TBRII binds to TAK1. Consistent with this
interaction, immunofluorescence microscopy showed that transiently over-expressed TAK1
and TBRII proteins co-localise in transfected cells. Unfortunately, the detection limits of
fluorescent immunocytochemistry in our hands meant that we were unable to ascertain co-
localisation of endogenous proteins. The specificity of the interaction was confirmed in that
there was no detectable interaction between TBRII and MLTKβ, a kinase closely related to
TAK1. Importantly, the interaction was also observed between endogenous TAK1 and TBRII
proteins in both mouse muscle myoblast and rat cardiomyocyte cell types. Further detailed
characterisation of the interacting sites are currently in progress, but the fact that three TAK1
isoforms (TAK1A, B and D) all interact with TBRII despite significant variation at the C-
terminus suggests that this interaction is not mediated at the C-terminal region of the TAK1
protein.
An indirect association between TAK1 and the TGFβ receptors has previously been proposed
as the X-linked inhibitor of apoptosis (XIAP) has been reported to interact with TAB1 [31]
and to promote association of TAB1 to the type I receptor, ALK5 [32]. The work described
here also indicates that TAK1 protein associates indirectly with ALK5, but that this may occur
through direct association with TBRII. Taken together, this evidence suggests that a molecular
complex is formed at the cell membrane composed of the TGFβ receptors and associated
proteins including Smads, XIAP and TAK1 (as described in Fig. 6). We hypothesise that when
the complex is exposed to TGFβ, TAK1 becomes activated through its association with the
TGFβ receptor complex and phosphorylates downstream MAPKKs. As described above, there
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is a wealth of evidence pointing to the importance of TGFβ and TAK1 in cardiac hypertrophy
so it is likely that these signalling events directly contribute to the hypertrophic response.
Furthermore, the direct interaction of TAK1 with TBRII potentially explains the rapid
activation of TAK1 (within 1 min) when extracellular TGFβ binds TBRII at the cardiomyocyte
cell surface [14]. However, further work is required to determine whether this occurs via
phosphorylation of TAK1 by the TGFβ receptor complex. There is considerable evidence for
synergy between the TAK-dependent and Smad-dependent TGFβ signalling pathways
[32-35]. TAK1 has been reported to interact with Smad 7 to inhibit TGFβ signalling by a
negative feedback mechanism [36,37]. More recently, TAK1 has been shown to interact with
Smads 1, 2, 3, 4, 5 and 6 [38] and to inhibit BMP signalling. These studies illustrate the close
integration of the Smad-dependent and TAK-dependent TGFβ signalling pathways but the
relative contributions of TAK-dependent and Smad-dependent pathways to cardiac
hypertrophy are still to be determined [39]. Nonetheless, the TAK1/TBRII interaction
described here potentially explains how two divergent, but linked, TGFβ responsive pathways
can respond to the same extracellular TGFβ signal (Fig. 6).
Our results show a specific interaction between the TGFβ receptor II and TAK1, which is likely
to play an important role in regulating TAK1 activity in cardiomyocytes. Further work is in
progress to characterise this interaction and investigate the molecular nature of the regulation
of TAK1 activity by TGFβ1 in cardiomyocytes. However, even at this early stage, this
interaction suggests how TAK1 can be rapidly activated by TGFβ1 and may be a critical
molecular mechanism in the initiation of cardiac hypertrophy.
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Fig. 1.
TAK1 immunoprecipitates with the Type II TGFβ receptor. The two upper panels show
immunoblot (IB) analysis of 293T cell lysates expressing Flag-TAK1 and HA-ALK1, HA-
ALK5 (type I TGFβ receptors) or HA-TBRII (Type II TGFβ receptor), as indicated.
Immunoprecipitation (IP) of TAK1 with anti-Flag antibody followed by immunoblot analysis
with anti-HA antibody (3rd panel) detects TBRII but not ALK1 or ALK5. Reciprocal
immunoprecipitation of the TGFβ receptors using anti-HA antibody, followed by immunoblot
analysis with anti-Flag (bottom panel), detects TAK1 protein only in the TBRII precipitate.
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Fig. 2.
(A) Cellular co-localisation of TAK1 and TBRII in Cos7 cells. Immunofluorescence
microscopy of Cos7 cells co-expressing recombinant TAK1 and TBRII proteins. Cells were
immunostained with (i) anti-TAK1 antibody and (ii) anti-TBRII antibody. The merged images
(iii and iv) show areas of co-localisation in yellow (nuclei were detected with DAPI staining).
Arrows indicate areas of co-localisation at the cell membrane. (B) In vitro binding assay with
TAK1 and the cytoplasmic domain of TGFβ receptor proteins, TBRII and endoglin (a Type
III TGFβ receptor). 35S-labelled TAK1 protein was generated by in vitro transcription and
translation and mixed with either glutathione S-transferase (GST) alone, GST–Endoglin fusion
protein or GST–TBRII in an in vitro binding assay. (i) Autoradiograph shows that 35S-TAK1
in the binding assay input fraction (IF) is seen after pull down (PD) of GST–TBRII, but not
GST–Endoglin. (ii) Coomassie staining of GST, GST–Endoglin fusion protein and GST–
TBRII fusion protein after SDS-PAGE, confirmed that GST and GST fusion proteins were
present in the binding assays.
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Fig. 3.
Immunoprecipitation of TBRII with three different isoforms of TAK1. (A) Immunoblot
analysis of Cos7 cell lysates expressing three TAK1 isoforms (A, B and D) and TBRII. TBRII
is detected by immunoblotting after immunoprecipitation of all three TAK1 isoforms. (*) =
Non-specific IgG band. (B) Diagrammatic representation of the three TAK1 isoforms used.
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Fig. 4.
TBRII and TAK1 interact specifically. Immunoblot analysis of Cos7 cell lysates co-expressing
TBRII with either HA-MLTKβ or HA-TAK1 shows that TBRII is not detectable after
immunoprecipitation of MLTKβ, but is detectable after immunoprecipitation of TAK1. (*) =
Non-specific IgG band.
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Fig. 5.
Endogenous TBRII and TAK1 co-immunoprecipitate. (A) Immunoblot analysis of C2C12 cell
lysates detects (i) endogenous TBRII after immunoprecipitation of endogenous TAK1 and (ii)
endogenous TAK1 after immunoprecipitation of endogenous TBRII. (B) (i) Immunoblot
analysis of H9C2 cardiomyocyte cell lysates with anti-TBRII antibody detects endogenous
TBRII after immunoprecipitation of endogenous TAK1. (ii) Further immunoblot analysis of
TAK1 precipitates from H9C2 cells with anti-ALK5 antibody also detects endogenous ALK5.
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Fig. 6.
Model of integrated Smad-dependent and TAK1-dependent TGFβ signalling. TGFβ1 is
induced by angiotensin II and binds to the type II TGFβ receptor (TBRII) on the cell membrane.
TBRII phosphorylates and activates ALK5 (the type I receptor), which can then propagate the
signal via Smad proteins to the nucleus where Smad-dependent TGFβ responsive genes are
regulated. ALK5 also binds to the X-linked inhibitor of apoptosis (XIAP), which associates
with TAB1 the major binding partner for TAK1 [32] and therefore indirectly links TAK1 to
the type I receptor. TAK1 also associates directly with the cytoplasmic domain of TBRII
forming a TGFβ-receptor protein complex at the cell membrane. Upon exposure to TGFβ, the
TBRII/TAK1 interaction would allow rapid activation of TAK1 via the TGFβ receptor
complex. Active TAK1 phosphorylates MKK3/6, which in turn activates p38 [20]. Smad-
dependent and TAK-dependent signals may act separately or in conjunction to affect a variety
of cell functions. TAK1 signalling appears to be particularly important in regulating
cardiomyocyte hypertrophy.
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